Zacks Bull and Bear of the Day Highlights
http://home.businesswire.com/portal/site/google/index.jsp
CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights
Gilead Sciences as the Bull of the Day and Sony Corporation
as the Bear of the Day.
Our Bull of the Day recommendation is for Gilead Sciences,
a biotechnology company that develops and markets drugs for
infectious diseases, including viral, fungal and bacterial infections.
The company also has specialized focus on developing drugs for
patients suffering from HIV/AIDS. We remain optimistic about
growth of HIV/AIDS franchise drugs Truvada and the recently
approved Atripla.
Fourth quarter earnings were above expectations specifically
on strong sales of the newly launched Atripla product.
In November the company completed the acquisition of Myogen
for $2.5 billion in cash. Although dilutive in the near-term,
this deal works to fill the pipeline gap beyond 2009.
Bush Asks for More Spending on HIV/AIDS
http://www.bloomberg.com/apps/news
Bush is asking $5.4 billion for AIDS research and prevention,
$300 million for malaria research, and $3 billion for the
Millennium Challenge Account, which targets aid to poor countries
that meet benchmarks in promoting democracy and rooting out
corruption.
.
|
